The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies

References

• Johnson PW, Sydes MR, Hancock BW, . Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 2010;28:3352–3359.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Kewalramani T, Nimer SD, . Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645–652.
   PubMed Web of Science ®Google Scholar
• Smith SD, Moskowitz CH, Dean R, . Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 2011;153:358–363.
   PubMed Web of Science ®Google Scholar
• Kaloyannidis P, Voutiadou G, Baltadakis I, . Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:451–457.
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Popplewell L, . Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011;90:803–808.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844–1854.
   PubMed Web of Science ®Google Scholar
• Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease. Eur J Radiol 2009;70:499–506.
   PubMed Web of Science ®Google Scholar
• Poulou LS, Thanos L, Ziakas PD. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur J Nucl Med Mol Imaging 2010;37:156–162.
   PubMed Web of Science ®Google Scholar
• Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 2010;15:750–759.
   PubMed Web of Science ®Google Scholar
• Terasawa T, Lau J, Bardet S, . Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906–1914.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009;50:257–260.
   Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, .; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571–578.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, .; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Haioun C, . Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma 2010;51:2171–2180.
   PubMed Web of Science ®Google Scholar
• Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging 2010;37:1821–1823.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Qian W, Somer EJ, . Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824–1833.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, .; the QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–536.
   PubMed Web of Science ®Google Scholar
• Reitsma JB, Glas AS, Rutjes AW, . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982–990.
   PubMed Web of Science ®Google Scholar
• Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol 2006;18:271–281.
   Web of Science ®Google Scholar
• Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005;365:1500–1505.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, . Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Deeks JJ, Egger M, . A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239–251.
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820–826.
   PubMed Web of Science ®Google Scholar
• O’Rourke K. Mixed means and medians: a unified approach to deal with disparate outcome summaries. Presented at 4th Symposium on Systematic Reviews: Pushing the Boundaries. 2002. Oxford: p 49.
   Google Scholar
• Boland GW, Dwamena BA, Jagtiani Sangwaiya M, . Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011;259:117–126.
   PubMed Web of Science ®Google Scholar
• Dwamena B. MIDAS: metaanalytical integration of diagnostic accuracy studies in Stata. 6th North American Stata Users Group Meeting, Boston, MA, August 2007. Available from: http://sitemaker.umich.edu/metadiagnosis/midas_home
   Google Scholar
• Dann EJ, Blumenfeld Z, Bar-Shalom R, . A 10-year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. Am J Hematol 2012;87:32–36.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Rigacci L, Stefoni V, . Early interim (18)F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 2012;39:4–12.
   PubMed Web of Science ®Google Scholar
• Markova J, Kahraman D, Kobe C, . Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma 2012;53:64–70.
   PubMed Web of Science ®Google Scholar
• Luminari S, Cesaretti M, Tomasello C, . Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. Leuk Lymphoma 2011;52:1689–1696.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Johnson JL, LaCasce AS, .; Cancer and Leukemia Group B. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 2011;117:5314–5320.
   PubMed Web of Science ®Google Scholar
• Le Roux PY, Gastinne T, Le Gouill S, . Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011;38:1064–1071.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Patti C, Viviani S, .; Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551–560.
   PubMed Web of Science ®Google Scholar
• Furth C, Amthauer H, Hautzel HJ, . Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma—results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 2011;22:1198–1203.
   PubMed Web of Science ®Google Scholar
• Barnes JA, LaCasce AS, Zukotynski K, . End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol 2011;22:910–915.
   PubMed Web of Science ®Google Scholar
• Cerci JJ, Pracchia LF, Linardi CC, . 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010;51:1337–1343.
   PubMed Web of Science ®Google Scholar
• Dann EJ, Bar-Shalom R, Tamir A, . A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma. Haematologica 2010; 95:1198–1206.
   PubMed Web of Science ®Google Scholar
• Furth C, Steffen IG, Amthauer H, . Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 2009;27:4385–4391.
   PubMed Web of Science ®Google Scholar
• Avigdor A, Bulvik S, Levi I, . Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol 2010;21:126–132.
   PubMed Web of Science ®Google Scholar
• Sher DJ, Mauch PM, Van Den Abbeele A, . Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:1848–1853.
   PubMed Web of Science ®Google Scholar
• Markova J, Kobe C, Skopalova M, . FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009;20:1270–1274.
   PubMed Web of Science ®Google Scholar
• Paolini R, Rampin L, Rodella E, . The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study. Nucl Med Rev Cent East Eur 2007;10:87–90.
   PubMedGoogle Scholar
• Gallamini A, Hutchings M, Rigacci L, . Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Goldsmith SJ, Leonard JP, . FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107:2678–2687.
   PubMed Web of Science ®Google Scholar
• Dann EJ, Bar-Shalom R, Tamir A, . Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007;109:905–909.
   PubMed Web of Science ®Google Scholar
• Querellou S, Valette F, Bodet-Milin C, . FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006;85:759–767.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, . Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006;17:1296–1300.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Rigacci L, Merli F, . The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475–481.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, . FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–59.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel NG, Fields PA, . Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160–1168.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Fischman A, Neuberg D, . FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85–92.
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nakamura F, Kanno T, . Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004;31:22–28.
   PubMed Web of Science ®Google Scholar
• Slabý J, Be lohlávek O, Táborská K, . [Predictive features of positron emission tomography after two cycles of induction therapy in malignant lymphoma]. Cas Lek Cesk 2002;141:312–315.
   PubMedGoogle Scholar
• Ziakas PD, Poulou LS. Improving outcome after positive interim PET in advanced Hodgkin's disease: reality vs expectation. Eur J Nucl Med Mol Imaging 2008;35:1573–1575.
   PubMed Web of Science ®Google Scholar
• Gallamini A, O’Doherty M. Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leuk Lymphoma 2011;52:583–586.
   PubMed Web of Science ®Google Scholar
• Devillé WL, Buntinx F, Bouter LM, . Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9.
   PubMedGoogle Scholar
• Lurati Buse GA, Koller MT, Grapow M, . The prognostic value of troponin release after adult cardiac surgery – a meta-analysis. Eur J Cardiothorac Surg 2010;37:399–406.
   PubMed Web of Science ®Google Scholar
• Whiting P, Rutjes AW, Reitsma JB, . Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189–202.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM 2007;100:193–201.
   PubMed Web of Science ®Google Scholar